Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism PTP1B inhibitors(Protein-tyrosine phosphatase 1B inhibitors), PTPN2 inhibitors(Tyrosine-protein phosphatase non-receptor type 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H24FN3O4S |
InChIKeyDVFCRTGTEXUFIN-GFCCVEGCSA-N |
CAS Registry2489404-97-7 |
Start Date- |
Sponsor / Collaborator |
Start Date09 Mar 2021 |
Sponsor / Collaborator AbbVie, Inc. [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IL | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | FR | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 09 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | FR | 09 Mar 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | lkyftvcfty(vgytcyobio) = ekukxoymld uurgseabvi (lqndxbnsox ) | - | 08 Dec 2024 | |||
Not Applicable | - | nanelmcfds(krghrvnjga) = a highly significant reduction in colony number was found in the presence of ABBV-CLS-484, IFN and venetoclax implying a direct inhibitory effect on AML growth and colony forming cells rwgniozauu (trcprtcxnz ) View more | - | 07 Dec 2024 |